Free Trial

Skye Bioscience (SKYE) News Today

Skye Bioscience logo
$2.98 -0.15 (-4.79%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$3.02 +0.04 (+1.21%)
As of 02/21/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Skye Bioscience to Present at TD Cowen Health Care Conference
Leo Miller: Page 3
Skye Bioscience, Inc. stock logo
Skye Bioscience (NASDAQ:SKYE) Stock Price Up 8.5% - Here's Why
Skye Bioscience (NASDAQ:SKYE) Shares Up 8.5% - What's Next?
Craig-Hallum Reaffirms Their Buy Rating on Skye Bioscience (SKYE)
Craig-Hallum Remains a Buy on Rezolute (RZLT)
Top Picks 2025- Skye Bioscience SKYE
Skye Bioscience, Inc. stock logo
Cantor Fitzgerald Predicts Skye Bioscience FY2025 Earnings
Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Skye Bioscience in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($1.14)
Skye Bioscience, Inc. stock logo
Cantor Fitzgerald Forecasts Skye Bioscience FY2025 Earnings
Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Skye Bioscience in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the c
Skye Bioscience, Inc. stock logo
Skye Bioscience (NASDAQ:SKYE) Shares Down 2.5% - Time to Sell?
Skye Bioscience (NASDAQ:SKYE) Stock Price Down 2.5% - Time to Sell?
Skye Bioscience, Inc. stock logo
Skye Bioscience (NASDAQ:SKYE) Shares Down 3% - Should You Sell?
Skye Bioscience (NASDAQ:SKYE) Shares Down 3% - What's Next?
Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE)
Skye Bioscience, Inc. stock logo
Skye Bioscience, Inc. (NASDAQ:SKYE) Sees Significant Drop in Short Interest
Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,590,000 shares, a decrease of 20.1% from the November 15th total of 1,990,000 shares. Based on an average daily trading volume, of 332,600 shares, the short-interest ratio is presently 4.8 days. Approximately 9.1% of the shares of the company are sold short.
Skye Bioscience, Inc. stock logo
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Buy" from Analysts
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price am
Skye Bioscience, Inc. stock logo
Point72 Asset Management L.P. Cuts Position in Skye Bioscience, Inc. (NASDAQ:SKYE)
Point72 Asset Management L.P. cut its stake in Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 25.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 416,424 shares of the company's stock after selling 143,576 shares
Skye Bioscience, Inc. stock logo
Point72 Asset Management L.P. Has $1.63 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE)
Point72 Asset Management L.P. decreased its stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 416,424 shares of the company's stock after
Skye Bioscience, Inc. stock logo
Skye Bioscience (NASDAQ:SKYE) Trading Down 12.7% - Time to Sell?
Skye Bioscience (NASDAQ:SKYE) Trading Down 12.7% - What's Next?
Skye Bioscience, Inc. stock logo
Skye Bioscience, Inc. (NASDAQ:SKYE) Stock Position Lifted by Baker BROS. Advisors LP
Baker BROS. Advisors LP raised its stake in Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 186.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,434,634 shares of the company's stock after buying an additional 934,634 shares durin
Skye Bioscience, Inc. stock logo
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Acquired by Baker BROS. Advisors LP
Baker BROS. Advisors LP increased its position in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 186.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,434,634 shares of the company's stock
Skye Bioscience, Inc. stock logo
Short Interest in Skye Bioscience, Inc. (NASDAQ:SKYE) Grows By 26.8%
Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,990,000 shares, a growth of 26.8% from the October 31st total of 1,570,000 shares. Based on an average daily volume of 314,400 shares, the days-to-cover ratio is presently 6.3 days. Currently, 11.3% of the company's shares are short sold.
Skye Bioscience (SKYE) Has a New Rating from Craig-Hallum
Skye Bioscience, Inc. stock logo
Skye Bioscience (NASDAQ:SKYE) Stock Price Down 1.5% - Should You Sell?
Skye Bioscience (NASDAQ:SKYE) Trading Down 1.5% - Time to Sell?
Oppenheimer Remains a Buy on Skye Bioscience (SKYE)
Skye Bioscience Reports Progress in Obesity Drug Trials
Skye Bioscience Q3 2024 Earnings Preview
Skye Bioscience (SKYE) Gets a Buy from Scotiabank
Skye Bioscience, Inc. stock logo
Skye Bioscience (SKYE) Scheduled to Post Earnings on Thursday
Skye Bioscience (NASDAQ:SKYE) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643772)
Skye Bioscience (SKYE) Receives a Buy from Craig-Hallum
Skye Bioscience, Inc. stock logo
Skye Bioscience (SKYE) Set to Announce Quarterly Earnings on Thursday
Skye Bioscience (NASDAQ:SKYE) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.
Skye Bioscience to Announce Third Quarter 2024 Results
Skye Bioscience, Inc. stock logo
Skye Bioscience, Inc. (NASDAQ:SKYE) Short Interest Update
Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,420,000 shares, a growth of 17.4% from the September 30th total of 1,210,000 shares. Approximately 7.8% of the company's shares are sold short. Based on an average daily volume of 325,000 shares, the short-interest ratio is currently 4.4 days.
Skye Bioscience Appoints New Chairman for Strategic Growth
Skye Bioscience names Grayson as Chairman of the Board
Get Skye Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.

SKYE Media Mentions By Week

SKYE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SKYE
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

SKYE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SKYE Articles
This Week

2

3

SKYE Articles
Average Week

Get Skye Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SKYE) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners